Skip to main content

Table 1 Patient characteristics (N = 70)a

From: The Carpentier-Edwards Perimount Magna mitral valve bioprosthesis: intermediate-term efficacy and durability

Demographics  
 Age, years 68 ± 1.6
 Gender  
  Men 36 (51 %)
  Women 34 (49 %)
Preoperative clinical and laboratory values  
 BMI,b kg/m2 26.5 ± 0.7
 Hematocrit, % 35.8 ± 0.7
 Creatinine (mg/dl) 1.6 ± 0.2
Disease acuteness  
 NYHA functional class  
  I or II 40 (57 %)
  III or IV 30 (43 %)
 Emergency operation  
  Yes 3 (4.3 %)
  No 67 (96 %)
 IABP use  
  Yes 3 (4.3 %)
  No 67 (96 %)
Cardiac comorbidities  
 Coronary artery disease 21 (30 %)
 EF, % 55 ± 1.2
 Moderately severe, or worse, MR 36 (51 %)
 Severe MS 21 (30 %)
 History of heart failure  
  Yes 22 (31 %)
  No 48 (69 %)
 Previous MI  
  Yes 10 (14 %)
  No 60 (86 %)
 Preoperative cardiogenic shock 9 (13 %)
  Yes
  No 61 (87 %)
 History of peripheral artery disease  
  Yes 4 (5.7 %)
  No 66 (94 %)
 Previous cardiac operation  
  Yes 30 (43 %)
  No 40 (57 %)
 Previous mitral valve repair or replacement  
  Yes 19 (27 %)
  No 51 (73 %)
 Preoperative AF  
  Yes 19 (27 %)
  No 51 (73 %)
 History of hypertension  
  Yes 53 (76 %)
  No 17 (24 %)
Noncardiac comorbidities  
 Previous stroke  
  Yes 8 (11 %)
  No 62 (89 %)
 History of carotid artery diseaseb  
  Yes 26 (37 %)
  No 43 (61 %)
 History of smoking  
  Yes 29 (41 %)
  No 41 (59 %)
 History of COPD  
  Yes 11 (16 %)
  No 59 (84 %)
 History of DM  
  Yes 17 (24 %)
  No 53 (76 %)
 History of renal disease  
  Yes 20 (29 %)
  No 50 (71 %)
  1. BMI body mass index, NYHA New York Heart Association, IABP intraaortic balloon pump, EF ejection fraction, AF atrial fibrillation, MI myocardial infarction, COPD chronic obstructive pulmonary disease, DM diabetes mellitus, MR mitral regurgitation, MS mitral stenosis
  2. aContinuous variables expressed as mean ± standard error of the mean (SE); categorical variables, as n (percentage)
  3. bData available for only 69 patients